-- About 235,000 people in the US will be diagnosed with lung cancer in 2021, with non-small cell lung cancer (NSCLC) accounting for 84 percent of all lung cancers(1)
-- ALK - anaplastic lymphoma kinase - is an important biomarker found in NSCLC, and targeted therapies have been shown to dramatically improve progression-free survival compared to the previous standard of care(2,3,4)
-- The VENTANA ALK (D5F3) CDx Assay(5) is now FDA approved as a companion diagnostic in four targeted treatments, providing more options to lung cancer patients
PR Newswire
TUCSON, Ariz., March 9, 2021
